Cochlear Limited's FY26 results showed an underlying net profit of $322 million, with challenges in achieving a higher net profit margin due to flat cochlear implant revenue and transitional costs. Sales revenue increased by 2% in constant currency to $2.3 billion, while gross margins decreased. The launch of the Nucleus Nexa System saw strong adoption, with Cochlear implant units increasing by 5%. Investments in R&D and strategic initiatives continued, despite impacts from cloud computing expenses and write-downs in innovation fund investments. The company remains committed to efforts in medicalizing hearing loss and enhancing referral pathways.
Key Points
Cochlear Limited reported an underlying net profit of $322 million in FY26, with a net profit margin of 14%, below the medium-term target of 18%.
Sales revenue increased by 2% in constant currency to $2.3 billion, while the gross margin declined from 74% to 71%.
Cochlear implant units grew by 5% to 56,692, with revenue flat in constant currency at $1.4 billion.
Free cash flow increased by $141 million to $264 million, supported by improved working capital.
The Nucleus Nexa System, a smart cochlear implant, was launched and achieved more than 95% of implant sales across developed markets.
Cloud computing investments and non-cash write-downs in innovation fund investments impacted significant items after tax.
R&D investment increased by 15% to support major product pipeline projects including a drug-eluting electrode and totally implantable cochlear implant.
Operating expenses declined by 1% due to disciplined management and actions to improve cost flexibility.
Cochlear remains focused on medicalizing hearing loss and strengthening adult referral pathways.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.